Xie et al., 2008 - Google Patents
Aberrant NF-κB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factorXie et al., 2008
View PDF- Document ID
- 3732464468778079179
- Author
- Xie T
- Aldape K
- Gong W
- Kanzawa T
- Suki D
- Kondo S
- Lang F
- Ali-Osman F
- Sawaya R
- Huang S
- Publication year
- Publication venue
- International journal of oncology
External Links
Snippet
Focal necrosis is a key pathologic feature that distinguishes glioblastoma from lower grade glioma. The presence of necrosis in a glioblastoma could promote its rapid growth and clinical progression. Focal necrosis of glioblastoma seems to be associated with thrombosis …
- 108010000499 Thromboplastin 0 title abstract description 88
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ronca et al. | Tumor angiogenesis revisited: regulators and clinical implications | |
| Haemmig et al. | miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas | |
| US12139535B2 (en) | Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents | |
| Sainson et al. | TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype | |
| AU2009331955B2 (en) | Biomarkers for inhibitors with anti-angiogenic activity | |
| Dikov et al. | Vascular endothelial growth factor effects on nuclear factor-κB activation in hematopoietic progenitor cells | |
| Marfia et al. | Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma | |
| Ndiaye et al. | VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness | |
| Umetani et al. | A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA | |
| JP2012196206A (en) | Met inhibitor for enhancing efficacy of radiotherapy | |
| EP3173483A1 (en) | Agents for the treatment of diseases associated with undesired cell proliferation | |
| US20220211848A1 (en) | Modulating gabarap to modulate immunogenic cell death | |
| US20200149042A1 (en) | Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy | |
| US20240280561A1 (en) | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers | |
| WO2004074511A1 (en) | Diagnosis and treatment of baff-mediated autoimmune diseases and cancer | |
| Xie et al. | Aberrant NF-κB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor | |
| US20210032334A1 (en) | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents | |
| US20080318241A1 (en) | Methods and Systems for Detecting Antiangiogenesis | |
| WO2019158512A1 (en) | Methods for the prognosis and the treatment of glioblastoma | |
| WO2012074842A2 (en) | Compositions and methods for treating neoplasia | |
| JP2007528208A (en) | Hypoxia-inducible protein 2 (HIG2) as a potential new therapeutic target for renal cell carcinoma (RCC) | |
| EP4213948A1 (en) | Methods for treating cancers with inhibitors targeting the role of grb2 in dna repair | |
| Taghi Khani et al. | Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms | |
| US20060216731A1 (en) | Methods and reagents for diagnosing and treating gliomas | |
| Sanders et al. | Activated leukocyte cell adhesion molecule impacts on clinical wound healing and inhibits HaCaT migration |